Cowen Remains Bullish Following Alexion Pharma's (ALXN) 3Q

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Cowen Remains Bullish Following Alexion Pharma's (ALXN) 3Q

Alexion Reports Third Quarter 2015 Results

October 29, 2015 6:30 AM EDT

Soliris® (eculizumab) Net Product Sales of $665.4 Million; Increased 20% Year-on-Year Despite 9% Currency Headwinds; 29% Volume Increase Year-on-Year -

- 2015 Non-GAAP EPS Guidance Increased to $4.92 to $4.97 -

Strensiq (asfotase alfa) Approved in the United States, European Union, Japan and Canada for Hypophosphatasia (HPP)

Kanuma (sebelipase alfa) Approved in the European Union for Lysosomal Acid Lipase Deficiency (LAL-D)

Completed Enrollment in Registration Trial of Eculizumab in Refractory MG and Progressed Registration Trials in Relapsing NMO and DGF

Advanced Complement and Metabolic Pipelines, Including ALXN 1210 and SBC-103

CHESHIRE, Conn.--(BUSINESS... More